Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

Abstract

Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.

• Authors: Brian Tomlinson
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 10 Pg. 936-45 (Oct 2006) ISSN: 1472-4472 [Print] England
• PMID: 17086939 (Publication Type: Journal Article, Review)

Chemical References

• Adjuvants, Immunologic
• Peptides
• Recombinant Proteins
• Growth Hormone-Releasing Hormone
• tesamorelin

Topics

• Adjuvants, Immunologic (adverse effects, chemical synthesis, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Cognition Disorders (drug therapy)
• Contraindications
• Diabetes Mellitus, Type 2 (drug therapy)
• Growth Hormone-Releasing Hormone (adverse effects, chemical synthesis, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• HIV Wasting Syndrome (drug therapy)
• HIV-Associated Lipodystrophy Syndrome (drug therapy)
• Hip Fractures (drug therapy)
• Humans
• Lipid Metabolism (drug effects)
• Peptides (adverse effects, chemical synthesis, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• Recombinant Proteins (therapeutic use)
• Sleep Wake Disorders (drug therapy)
• Structure-Activity Relationship